Skip to main navigation
AASLD Family of Websites:
The Liver Meeting
AASLD.org
AASLD Foundation
LiverLearning
Careers
Journals
Liver Fellow Network
HCV Guidelines
Menu
TLM Main Navigation
Registration
Attendee Information
Venue
Hotels
Travel
Visa Letter
Exhibit Hall
Program
Program at-a-Glance
Schedule
Speakers
Special Programs
CE Credits
Journey Maps
Events
Networking Events
Get TLM Updates
TLM Utility Nav
For Media
For Industry
Cannabis and Cannabidiol Hepatotoxicity
Nov
17
2024
Convention Center: Room 25 B
7:00 AM - 7:45 AM
Ticketed Event
World Class Speakers
MP
Discussion Leader
Melissa Palmer, MD, MD, FAASLD
CEO Liver Consulting LLC
RV
Discussion Leader
Raj Vuppalanchi, MD, FAASLD
Description
Speakers discuss the data regarding hepatotoxicity from cannabis and cannabidiol compounds.
Journey Maps
Acute Liver Failure
Acute-on-Chronic Liver Failure
Drug-Induced Liver Injury
Objectives
Explain the liver toxicity risk associated with cannabis products.
Describe the difference between cannabidiol (CBD) and cannabis in terms of liver injury and relative toxicity.